Obscure Cannabis Components ‘Hold Therapeutic Promise’ For Treating Skin Problems Like Acne and Psoriasis, Study Finds

August 25, 2023 · marijuanamoment.net

A new study suggests that some lesser-known cannabinoids produced by hemp and marijuana—with names like THCV, CBDV, CBC, CBM and CBN—may help treat dermatological diseases such as psoriasis, eczema and acne.

“The findings of this review suggest that minor cannabinoids hold therapeutic promise in the management of dermatological diseases,” says the study, published this week in the peer-reviewed journal Molecules. “Incorporating minor cannabinoids into dermatological therapies could potentially offer novel treatment options of patients and improve their overall well-being.”

To reach those conclusions, Polish researchers Emilia Kwiecień and Dorota Kowalczuk reviewed existing literature published in scientific journals and found that minor cannabinoids “exhibit diverse pharmacological activities, including anti-inflammatory, analgesic, antimicrobial, and anti-itch properties.” Some studies “reported their efficacy in mitigating symptoms associated with dermatological diseases such as psoriasis, eczema, acne and pruritus,” authors noted.

Certain minor cannabinoids seemed to be especially suited for treating specific diseases. “CBDV, with its anti-inflammatory properties, can be used to alleviate skin symptoms such as itching and swelling in the treatment of” atopic dermatitis (AD), the authors wrote, for example. The cannabinoid also, “due to its anti-inflammatory and antioxidant properties, can have a healing effect on acne lesions.”

“Other recently discovered cannabinoids such as CBM and CBE have also demonstrated anti-inflammatory potential,” the study continues. “They represent a novel alternative for conducting scientific research regarding specific disease conditions. Similarly, CBC, with its anti-inflammatory and antioxidant effects, may have a beneficial impact on the treatment of acne, psoriasis and AD.”

THCV, meanwhile, “shows many promising properties in combatting acne,” as it may help regulate sebum production. It also “exhibits anti-inflammatory and antibacterial properties that can help alleviate inflammation and combat the bacteria responsible for acne development.”

All told, researchers identified possible therapeutic applications of the minor cannabinoids CBDV (cannabidivarin), CBDP (cannabidiforol), CBC (cannabichromene), THCV (tetrahydrocannabivarin), CBGA (cannabigerolic acid), CBG (cannabigerol) and CBN (cannabinol), as well as more recently discovered cannabinoids CBM (cannabimovone) and CBE (cannabielsoin).

The effects are believed to be the result of cannabinoids interacting with the body’s endocannabinoid system, “a central regulatory system responsible for maintaining the health and proper functioning of almost every organism,” the study’s authors explain. “Increasing evidence suggests that endocannabinoid signaling plays a crucial role in regulating biological processes in the skin. Many skin functions, such as immune response, cell proliferation, differentiation, and survival, are at least partially regulated by the endocannabinoid system, and suppressing skin inflammation is one of its strongest functions.”

Topical applications of minor cannabinoids may even help mitigate the effects of aging, the study said.

Authors emphasized that more research is needed on minor cannabinoids “to confirm their effectiveness and safety,” but acknowledged there are still barriers to progress.

“The impact on the nervous system, issues pertaining to product quality and regulation, as well as ethical and legal aspects, including those concerning legality, require comprehensive consideration,” they wrote. “Therefore, despite the promising therapeutic prospects, the utilization of cannabinoids, especially the minor cannabinoids, necessitates further research, regulations and a balanced approach to ensure benefits while minimizing potential health and societal risks.” (Full Story)

In categories:Medical Research
Next Post

States That Legalized Medical Marijuana Saw Nearly 20 Percent Drop In Foster Care Cases For Parental Drug Misuse, Study Finds

States that legalized medical marijuana saw a nearly 20 percent drop in the number of children entering foster care due to parental drug misuse after three years of the reform, a new study found. Legalizing for adult use, meanwhile, was…
Previous Post

What 3 Common Health Conditions Can THC Help Treat in Humans?

3 Common Health Conditions That THC Can Treat The number of conditions that cannabis has been studied to treat continues to grow each year. There are some health conditions where psychoactive THC (tetrahydrocannabinol) and calming CBD (cannabidiol) work better than the other, with research to back…
Random Post

Is There a Solution to the Cash Crunch?

While the past few years have been no picnic for companies struggling to turn a profit, it looks like 2023 could be the most challenging year yet. A triple threat of high-interest debts, inflation, and overdue taxes is looming over some entities,…
Random Post

From Legalize Weed to Shut It Down? - Connecticut Lawsuit Aims to Shut Down All Legal Cannabis Programs in the State

A legal case has been initiated against the Stamford Zoning Board, aiming to exert control over Connecticut's emerging cannabis sector. In addition to addressing city-specific regulations, the lawsuit, which portrays the state's Social Equity Council as a questionable initiative, holds the potential…
Random Post

Study: Cannabis Legalization Does Not Lead to Increased Use of Other Drugs

A new report found cannabis legalization does not lead to an increase in substance use disorders or the increased use of illicit drugs. Cannabis legalization had not led to an increase in substance use disorders or increased use of other…
Random Post

Marijuana advertisers face hurdles with Twitter’s newest ad policies

Twitter might have further eased its rules for cannabis advertising, but the changes don’t seem to have made it any easier for marijuana businesses to take advantage of the social media platform’s wide reach. Regulatory red tape, Twitter’s unfamiliarity with…